BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 536 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $273,026 | -18.1% | 4,011 | -1.8% | 0.00% | -50.0% |
| Q2 2023 | $333,299 | +10.6% | 4,083 | +0.5% | 0.00% | +100.0% |
| Q1 2023 | $301,362 | -10.8% | 4,062 | -0.3% | 0.00% | -50.0% |
| Q4 2022 | $337,824 | +20.2% | 4,076 | +312.6% | 0.00% | +100.0% |
| Q3 2022 | $281,000 | -16.1% | 988 | +2.2% | 0.00% | -50.0% |
| Q2 2022 | $335,000 | -25.6% | 967 | -6.9% | 0.00% | 0.0% |
| Q1 2022 | $450,000 | -31.2% | 1,039 | -17.8% | 0.00% | -33.3% |
| Q4 2021 | $654,000 | -1.2% | 1,264 | -7.5% | 0.00% | 0.0% |
| Q3 2021 | $662,000 | +12.6% | 1,367 | +4.7% | 0.00% | 0.0% |
| Q2 2021 | $588,000 | -26.7% | 1,306 | -37.8% | 0.00% | +50.0% |
| Q1 2021 | $802,000 | +118.5% | 2,100 | +81.8% | 0.00% | 0.0% |
| Q4 2020 | $367,000 | +28.3% | 1,155 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $286,000 | -6.2% | 1,155 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $305,000 | +39.3% | 1,155 | 0.0% | 0.00% | +100.0% |
| Q1 2020 | $219,000 | -13.8% | 1,155 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $254,000 | +12.4% | 1,155 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $226,000 | – | 1,155 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brown Capital Management | 2,119,107 | $256,179,000 | 3.12% |
| STONE RUN CAPITAL, LLC | 42,925 | $5,189,000 | 2.67% |
| 440 INVESTMENT GROUP, LLC | 27,820 | $3,363,000 | 2.56% |
| Summit Creek Advisors LLC | 106,517 | $12,877,000 | 2.54% |
| MAIRS & POWER INC | 1,444,480 | $174,623,000 | 2.10% |
| QUANTUM CAPITAL MANAGEMENT | 57,094 | $6,902,000 | 1.63% |
| Select Equity Group, L.P. | 1,709,914 | $206,711,503,000 | 1.57% |
| FRIESS ASSOCIATES LLC | 144,610 | $17,482,000 | 1.53% |
| Tygh Capital Management, Inc. | 61,813 | $7,473,000 | 1.49% |
| First Light Asset Management, LLC | 38,654 | $4,673,000 | 1.48% |